Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05780736 · ClinicalTrials.gov registry record
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
A clinical trial, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- 33
- Enrollment target
NCT05780736 is a clinical trial that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants.
The verdict
NCT05780736 was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-08-04 |
| Est. Completion | 2024-08-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05780736
The ClinicalTrials.gov registry entry for NCT05780736 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05780736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05780736 about?
NCT05780736 is a clinical study titled "A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer". The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
What is the current status of trial NCT05780736?
This trial is currently terminated. The enrollment target is 33 participants. The study started on 2023-08-04. Estimated completion is 2024-08-23.
Who is sponsoring clinical trial NCT05780736?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.